Clinical

Dataset Information

0

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer


ABSTRACT: This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).

DISEASE(S): Metastatic Colorectal Cancer,Histologically Confirmed Adenocarcinoma Of The Colon Or Rectum That Is Metastatic (stage Iv).,Colorectal Cancer,Colorectal Neoplasms,Neoplasms

PROVIDER: 2213684 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2272736 | ecrin-mdr-crc
2013-09-17 | GSE50103 | GEO
2013-09-17 | E-GEOD-50103 | biostudies-arrayexpress
| 2075225 | ecrin-mdr-crc
| 2633522 | ecrin-mdr-crc
| 2630804 | ecrin-mdr-crc
| 2633714 | ecrin-mdr-crc
| 2630485 | ecrin-mdr-crc
2014-09-10 | GSE54483 | GEO
| 2622791 | ecrin-mdr-crc